

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number		10/650,110
Filing Date		August 26, 2003
First Named Inventor		Yanhong Zhu
Art Unit		Unknown
Examiner Name		Unknown
Total Number of Pages in This Submission	5	Attorney Docket Number 13131-0292 (44378-287574)

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO/SB/08A Form (3pp) References (20)
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	John K. McDonald, Ph.D. - Reg. No. 42,860
Signature	
Date	November 24, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	John K. McDonald, Ph.D. - Reg. No. 42,860
Signature	
Date	November 24, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Yanhong Zhu et al.

Serial No. 10/650,110

Filed: August 26, 2003

For: A Method of Treating and Preventing
Alzheimer Disease Through
Administration of Delipidated Protein
and Lipoprotein Particles



Art Unit: Unknown

Examiner: Unknown

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

John K. McDonald, Ph.D.
Reg. No. 42,860

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 13131-0292 (44378-287574)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 24, 2003.

John K. McDonald, Ph.D. - Reg. No. 42,860

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	
Examiner Name	
Attorney Docket Number	13131-0292 (44378-287574)

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS


[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.



Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	
		Examiner Name	
Sheet 2	of 3	Attorney Docket Number	13131-0292 (44378-287574)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
✓	18	BARRES, BEN A., et al., Cholesterol – Making or Breaking the Synapse, Science, November 9, 2001, pp. 1296-1297, vol. 294.	
✓	19	BURNS, M. et al., Use of in vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease, Neurochem Res, July 2003, pp. 979-86 (abstract only), vol. 28.	
✓	20	COOPER, J., Dietary Lipids in the Aetiology of Alzheimer's Disease: Implications for Therapy, Drugs Aging, 2003, pp. 399-418 (abstract only), vol. 20, no. 6.	
✓	21	GLODE, TODD E., et al., Cholesterol Modulation as an Emerging Strategy for the Treatment of Alzheimer's Disease, Drug Discovery Today, Oct. 15, 2001, pp. 1049-1055 (abstract only), vol. 6, no. 20.	
✓	22	KOUDINOV, A.R., et al., Alzheimer's Amyloid Beta Interaction with Normal Human Plasma High Density Lipoprotein: Association with Apolipoprotein and Lipids, Clin Chim Acta, February 23, 1998, pp. 75-84 (abstract only), vol. 270, no. 2.	
✓	23	KOUDINOV, A.R., et al., Alzheimer's Soluble Amyloid Beta Protein is Secreted by HepG2 Cells as an Apolipoprotein, Cell Biol Int., May 1997, pp. 265-71 (abstract only), vol. 21, no. 5.	
✓	24	KOUDINOV, A.R., et al., Biochemical Characterization of Alzheimer's Soluble Amyloid Beta Protein in Human Cerebrospinal Fluid: Association with High Density Lipoproteins, Biochem Biophys Res Commun., June 25, 1996, pp. 592-7 (abstract only), vol. 223, no. 3.	
✓	25	KOUDINOV, ALEXEI R., et al., Cholesterol's Role in Synapse Formation, Science, November 9, 2001, pp. 2213, vol. 294.	
✓	26	KOUDINOVA, N.V., et al., Amyloid Beta, Neural Lipids, Cholesterol and Alzheimer's Disease, Soc. Neuroscience Abstract Viewer and Itinerary Planner, Nov: 2-7, 2002, pp. Abstract No. 21.10, vol. 2002.	
✓	27	LIPID SCIENCES, Lipid Technology, http://www.lipidsciences.com/technology.html , August 25, 2001, pp. 1-4.	
✓	28	MAUCH, DANIELA H., et al., CNS Synaptogenesis Promoted by Glia-Derived Cholesterol, Science, November 9, 2001, pp. 1354-1357, vol. 294.	
✓	29	REFOLO, L.M., et al, Cholesterol Metabolism: A Potential Target for Alzheimer's Disease Therapy, Soc. Neuroscience Abstracts, 2001, pp. 1518, vol. 27, no. 2.	
✓	30	YOSHIDOME, HIROAKI et al., Serum Amyloid A and P Protein Levels are Lowered by Dextran Sulfate Cellulose Low-Density Lipoprotein Apheresis, Artif Organs, 1998, pp 144-148, vol. 22, no. 2.	

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number

(use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	
Examiner Name	
Attorney Docket Number	13131-0292 (44378-287574)

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

 T^2

31	Zetia (ezetimibe), http://www.zetia.com/ezetimibe/zetia/hcp/product_highlights/index.jsp , July 18, 2003, pp. 1-2.
----	--

32	Zetia: Complements Statin with a Unique Mechanism, http://www.zetia.com/ezetimibe/zetia/hcp/mechanism_of_action/index.jsp , July 18, 2003, pp. 1-2..
----	--

Date
Considered

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.